Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management
Status:
Recruiting
Trial end date:
2023-03-15
Target enrollment:
Participant gender:
Summary
Appropriately, half of the global population is infected with H. pylori, and it is now
recognized that it causes at least 95% of all gastric cancers. Currently, the main challenge
in the field of H. pylori infection is the rapidly increasing antibiotic resistance
worldwide, which is causing a decline in the effectiveness of currently available eradication
regimens.
The aim of the study is to assess the safety and efficacy of different H. pylori
vonoprazan-based regimens compared to the commonly used standard triple therapy composed of
Clarithromycin, Amoxicillin, and Proton pump inhibitor to eradicate H. pylori infection in
treatment-naive patients through the determination of each regimen eradication rate and
reported safety profile